Tirzepatide Matches Competitor's Cardioprotective Benefits for Diabetics

(MedPage Today) — The dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) was just as cardioprotective as the GLP-1 drug dulaglutide (Trulicity) in patients with type 2 diabetes and atherosclerotic cardiovascular disease, a large…

Source link : https://www.medpagetoday.com/cardiology/prevention/119074

Author :

Publish date : 2025-12-17 22:47:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

Tirzepatide Matches Competitor’s Cardioprotective Benefits for Diabetics

Gout and Its Comorbidities

The Food Chain – What is the ultimate hangover cure?

Related Posts

Woman speaks of unbearable pain of living with endometriosis

Healthy Diet May Cut Cancer Survivors’ Premature Aging Risk

Chronic Rhinosinusitis Tied to Increased Cancer Risk

Lobectomy: Viable Alternative in Medullary Thyroid Carcinoma

Arranging social care can be “horrendous”, Baroness Casey tells BBC

AI Tool Could Help Identify Osteoporosis and Osteopenia Risk

Woman speaks of unbearable pain of living with endometriosis

Healthy Diet May Cut Cancer Survivors’ Premature Aging Risk

Chronic Rhinosinusitis Tied to Increased Cancer Risk

Lobectomy: Viable Alternative in Medullary Thyroid Carcinoma

Arranging social care can be “horrendous”, Baroness Casey tells BBC

AI Tool Could Help Identify Osteoporosis and Osteopenia Risk

PIP Matches PrEP for Low-Risk HIV

Semaglutide for Alzheimer’s: What the EVOKE Trials Taught Us

Categories

Archives